This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Afluria industry.
What is the anticipated market size of the afluria industry over the next few years?
The Afluria market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increasing incidence of influenza, growing geriatric population, rising healthcare expenditure, increasing awareness of vaccine safety, and increase in public health campaigns.
The Afluria market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to increasing government support, growing focus on preventative healthcare, rising vaccine hesitancy mitigation efforts, expansion of healthcare systems, and rising income levels in emerging economies. Major trends in the forecast period include telehealth integration for vaccination consultations, investment in cold chain logistics, integration of artificial intelligence in vaccine development, government incentives for vaccination, and collaboration with technology companies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19861&type=smp
What emerging drivers are expected to shape the future of the afluria market?
The growing prevalence of influenza is expected to propel the growth of the afluria market going forward. Influenza, commonly known as the flu, is an infectious respiratory disease caused by influenza viruses that can lead to mild to severe illness, with symptoms including fever, cough, sore throat, body aches, and fatigue. The increasing prevalence of influenza is attributed to factors such as heightened public awareness of the disease, rising incidence rates from virus mutations, and greater demand for vaccinations, especially among vulnerable groups like the elderly. Afluria is used as a vaccine to prevent influenza by stimulating the immune system to produce antibodies against the flu virus. For instance, in November 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, as of October 16, 2024, influenza positivity rose to 2.3% in week 41, up from 2% the previous week, with the highest rates (5.1%) seen in those aged 5 to 14 years. Therefore, the growing prevalence of influenza is driving the growth of the afluria market.
The Growing Need For Influenza Vaccines Among Older Adults
The growing geriatric population is expected to propel the growth of the afluria market going forward. The geriatric population refers to individuals who are typically aged 65 and older and characterized by unique health needs and challenges associated with aging. The geriatric population is growing due to a combination of declining fertility rates and increasing life expectancy, resulting in a larger proportion of older individuals within the overall population. The geriatric population, which is particularly vulnerable to severe illness and mortality from influenza, necessitates effective vaccination strategies such as afluria to protect older adults and reduce flu-related health complications. For instance, in July 2024, according to a report published by the House of Commons Library, a UK-based government agency, the UK’s population is aging, with around 12.7 million people aged 65 and over in 2022, accounting for 19% of the total population, and this number is expected to rise to 22.1 million, or 27% of the population, by 2072. Therefore, the growing geriatric population is driving the growth of the afluria market.
What emerging segments are shaping the future landscape of the afluria industry?
The afluria market covered in this report is segmented –
1) By Formulation: Pre-Filled Syringes; Multi-Dose Vials
2) By Clinical Indication: Influenza Prevention
3) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Government Supplier
4) By End Users: Pediatric; Adult; Geriatric
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/afluria-global-market-report
What are the top market trends driving innovation in the afluria industry?
The key trend in the afluria market is focusing on developing innovative solutions such as a nano-sized particle-based vaccine to enhance vaccine efficacy, stability, and targeted delivery. A nanoparticle-based vaccine refers to a vaccine that uses tiny particles, often in the nanometer range, to deliver antigens more efficiently and improve immune response. For instance, in March 2024, Cadila Pharmaceuticals Ltd., an India-based pharmaceutical company, launched the Cadiflu Tetra Vaccine, an advanced quadrivalent influenza vaccine aimed at preventing seasonal influenza. This vaccine targets four strains of the influenza virus, specifically subtypes A and B, providing broader protection against flu epidemics. It incorporates key proteins such as hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) in a single formulation, contributing to a qualitatively superior vaccine with a better safety profile compared to traditional vaccines.
How are key players in the afluria market strengthening their market position?
Major companies operating in the afluria market include CSL Seqirus
Which geographic areas are contributing significantly to the growth of the afluria sector?
North America was the largest region in the afluria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afluria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Afluria Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19861
Need Customized Data On Afluria Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19861&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
